Upstream Bio
Developing verekitug, a TSLP-receptor antibody for severe respiratory diseases.
$6.69
After-hours close+0.01 (+0.15%)
At close$6.68(−1.62%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.73 | — | — |
| Aug 2026 | −$0.73 | −$0.73 | −0.6% |
| May 2026 | −$0.74 | −$0.75 | −1.2% |
| Mar 2026 | −$0.73 | −$0.79 | −8.2% |
| Nov 2025 | −$0.78 | −$0.63 | +19.2% |
The latest year is open to everyone — the 7 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Oct 2024 | — | — | — |
| Dec 2023 | |||
| Sep 2023 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | −$0.73 | — | — | $522.5K | — | — |
| Aug 11, 2026 | −$0.73 | −$0.73 | −0.6% | $561.4K | $773.0K | +37.7% |
| May 13, 2026 | −$0.74 | −$0.75 | −1.2% | $1.0M | $1.0M | +0.6% |
| Mar 26, 2026 | −$0.73 | −$0.79 | −8.2% | $584.0K | $668.0K | +14.4% |
| Nov 5, 2025 | −$0.78 | −$0.63 | +19.2% | $521.6K | $683.0K | +31.0% |
The latest year is open to everyone — the 7 quarters behind it read with an account. Sign in | ||||||
| Aug 6, 2025 | ||||||
| May 6, 2025 | ||||||
| Mar 13, 2025 | ||||||
| Nov 7, 2024 | ||||||
| Oct 11, 2024 | — | — | — | — | — | — |
| Dec 31, 2023 | ||||||
| Sep 30, 2023 | ||||||